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Dyslipidaemia tends to occur in children and adolescents and steadily worsens 
through to adulthood. The abnormal lipid profile in children with this disease is like 
what we see in adults with premature cardiovascular disease (CVD). Identifying 
children with dyslipidaemia and successfully improving their lipid profile may 
reduce their risk of accelerated atherosclerosis and premature CVD. In those chil-
dren with severe dyslipidaemia due to a family history, treatment is used to decrease 
the risk of cardiogenic events. Screening for lipid disorders in children is based on 
the rationale that early identification and control of paediatric dyslipidaemia will 
reduce the risk and severity of cardiovascular complications in adulthood. Though 
lipid disorders and associated diseases are rare in children in Africa, there has been 
little research in this field. Emerging research indicates that obesity and cholesterol 
concerns is on the rise within children and adolescents of African descent. The 
definition of paediatric dyslipidaemia and the approach to screening, and diagnosis 
of lipid disorders in children are discussed in this chapter.
Keywords: hypercholesterolemia, lipid disorders, cardiovascular risk,  
dyslipidaemia, lipoprotein cholesterol
1. Introduction
Overweight and obesity are proven cardiovascular risk factors for both 
adults and children [1]. These conditions are associated with increasing risk of 
dyslipidaemia [2, 3]. Unfortunately, the world has experienced a huge increase 
in obesity with a parallel increase in the risk factor for cardiometabolic disease 
characterised by insulin resistance, dyslipidaemia, and hypertension, known 
together as metabolic syndrome [4]. These conditions were previously unheard of 
in children and adolescents but are now documented in the literature [5]. Current 
evidence has shown that atherosclerosis, predominantly adult diseases marked 
by the accumulation of fatty material on the inner wall of the arteries, starts 
in childhood as an alteration of lipid concentration and can be related through 
puberty to modifications that contribute to the development of this disorder. 
Children and adolescents with elevated cholesterol levels are more likely to 
experience dyslipidaemia in adults than their counterparts in the same population 
[6, 7]. Identification of dyslipidaemia is therefore essential for the prevention or 
cessation of atherosclerotic processes during childhood and ultimately for the 
prevention of premature cardiovascular disease.
Lipid disorders and related diseases are rare in children and adolescents in Africa 
and there is a scarcity of literature on this topic. However, emerging data indicates 
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that the incidence and prevalence of obesity and dyslipidaemia is on the rise in the 
population of African children and adolescents, partially due to shifts in economic 
and lifestyle towards the trends in the Western world [8]. Serious comorbidities, 
complications, and cardiovascular risk factors, including obesity, diabetes mellitus, 
hypertension, and smoking, are correlated with dyslipidaemia. As a result, more 
attention tends to be paid to the increasing problems of dyslipidaemia among the 
African population in recent years. The key objectives of this chapter are to discuss 
the burden of dyslipidaemia, diagnosis, risk factors and health problems, as well as 
gaps in awareness of dyslipidaemia in children and adolescents in Africa.
2. What is dyslipidaemia in children?
From a general biology perspective, lipids are organic and water insoluble 
compounds which include fatty acids, triglycerides, and cholesterol. Lipoproteins 
are also soluble in watery environments of human body. Chylomicrons are formed 
in the intestine after fat is digested. They are then moved to the fat tissue, muscle, 
and liver. Chylomicrons are hydrolysed into free fatty acids and then metabolised to 
low density lipoprotein cholesterol (LDL-C) (the major carrier of cholesterol to tis-
sues). Cholesterol is a fatty substance that passes through high density lipoprotein 
cholesterol (HDL-C) to peripheral tissues and then to the liver. Abnormalities in the 
pathway lead to dyslipidaemia.
Dyslipidaemias are lipoprotein metabolism disorders that result in the abnor-
malities of high total cholesterol (TC), high LDL-C, high non-HDL-C, high 
triglycerides, and low HDL-C. The HDL and LDL cholesterol monitor the amount 
of cholesterol that can occur in the body, and if there is an excess it can increase 
the risk of cardiovascular events. Other forms of dyslipidaemia also include high 
phospholipids and combined dyslipidaemia.
Since cholesterol is an essential component of human cells, cholesterol may also 
be generated by individual cells or introduced to the body via our diets. However, 
when cholesterol levels are increased for whatever reason, they may be bad for the 
human body. Lipid levels in children younger than 19 years of age are different from 
lipid levels in adults and vary for the same age in different patients. As an infant, 
the levels of cholesterol and triglycerides are lower than when a person is an adult. 
Levels grow steadily during the first year of adolescence, then increase more slowly 
until they reach the age of 9 to 11 years, but then increase slightly faster until they 
reach adulthood. At puberty, low-density lipoprotein cholesterol (LDL-C) blood 
levels decrease by about 10% to 20% or more, whereas high-density lipoprotein 
(HDL-C) levels increase by 50% or more.
The plasma levels of serum lipids and lipoproteins as recommended are in 
Table 1. Normative data are used to establish cut-off points and identify ranges 
of acceptable, borderline, and abnormal levels as shown. In Table 1, the values 
for plasma lipid and lipoprotein levels are taken from the National Cholesterol 
Education Program’s (NCEP) Expert Panel on Cholesterol Levels in Children as they 
were observed. Non-HDL-C values from the Bogalusa Heart Study are equivalent 
to the NCEP Paediatric Panel cut-off points for LDL-C. Values for plasma Apo B 
and Apo A-1 come from the National Health and Nutrition Examination Survey 
III (NHANES III). As a usually occurring wide range, the threshold points for high 
and borderline-high values reflect roughly the 95th and 75th percentiles, respec-
tively. These values fall into the range of the 10th percentile of the standard range 
for HDL-C and ApoA-1. It should be noted that the ranges for plasma lipoprotein 
cholesterol in Table 1 are consistent with the guidelines of the National Heart, 
Lung and Blood Institute, the American Academy of Paediatrics and the American 
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College of Cardiology. However, these cut-off points have not been validated as 
accurate benchmarks for accelerated atherosclerosis and CVD events in the African 
children’s population.
3. Problem of dyslipidaemia in children
Atherosclerosis and cardiovascular disease (CVD) are the major health problems 
associated with dyslipidaemia. These disorders are vascular problems associated 
with more than 17 million deaths worldwide in 2015, a rise of 12.5 per cent from 2005 
onwards [9]. While it is acknowledged that a diet low in saturated fat and regulated 
cholesterol levels are essential for heart health, it is also determined that certain foods 
can increase the risk of coronary artery disease (CAD) and other cardiovascular 
problems [10–12]. Although the prevalence of dyslipidaemia has gradually decreased 
in several high-income and developing countries over the last 20 years, it is currently 
predicted that the incidence of dyslipidaemia will increase in African countries due to 
the rapid change in lifestyles to high-income and developed countries [13].
As far back as 1981, evidence from different studies among Caucasians showed 
that in childhood, serum levels of cholesterol and triglycerides could rise to levels 
similar to those seen in young adults at around 2 years of age [14]. Concentrations 
and turnover of such important molecules in blood lipid concentrations do occur in 
children. Over the years, researchers have found that if there is a family history of 
CVD, there is greater concern that a CVD will be developed.
There is ample evidence which suggests that there are more children and ado-
lescents with the hyperlipidemia disease. From the 1988–1994 National Health and 
Nutrition Survey, it was shown that 10 percent of teenagers had the total cholesterol 
greater than 200 mg per dL [15]. Also, the newly generated age- and gender-specific 
lipoprotein from data of the Child and Adolescent Trial for Cardiovascular Health 
showed that over one-tenth of children aged 9 to 10 years had TC levels greater than 
200 mg per dL [16].
While data on the severity of dyslipidaemia among children and adolescents in 
Africa are scarce in published literature, a few observational studies have reported 
hypercholesterolemia prevalence and associated risk factors. In the Ghana School 







TC <170 (4.4) 170 to 199 (4.4 to 5.2) ≥200 (5.2)
LDL-C <110 (2.8) 110 to 129 (2.8 to 3.3) ≥130 (3.4)
Non-HDL-C <120 (3.1) 120 to 144 (3.1 to 3.7) ≥145 (3.8)
ApoB <90 (2.3) 90 to 109 (2.3 to 2.8) ≥110 (2.8)
TG
0 to 9 years <75 (0.8) 75 to 99 (0.8 to 1.1) ≥100 (1.1)
10 to 19 years <90 (1 mmol/L) 90 to 129 (1 to 1.5) ≥130 (1.5)
HDL-C >45 (1.2) 40 to 45 (1 to 1.2) <40 (1)
ApoA-1 >120 (3.1) 115 to 120 (3 to 3.1) <115 (3)
Adapted from expert panel on integrated guidelines for cardiovascular health and risk reduction in children and 
adolescents, national heart, lung, and blood institute [3].
Table 1. 
Acceptable, borderline-high, and high plasma lipid and lipoprotein ranges for children and adolescents.
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hyperlipidemia was 12.1% for TC, 4.5% for TG, 28.4% for HDL-C and 9.2% for LDL-C 
[17]. Another study conducted among adolescent school children in the Eti-Osa Local 
Government Area of Lagos State, Nigeria, recorded that only 3.6 per cent of partici-
pants had TC greater than 200 mg/dL [18]. The highest prevalence of high TC among 
Angolan pre-pubertal adolescents, 7 to 11 years of age, was estimated to be 69.2% [19].
4. Causes of dyslipidaemia
Dyslipidaemias in children and adolescents can be inherited and/or acquired. 
Acquired causes of dyslipidaemia can be nutritional or secondary to other diseases. 
Excessive dietary intake of saturated and trans fats can be a major cause of dyslipi-
daemia. Hereditary types are referred to as primary dyslipidaemias which includes 
monogenetic and polygenic defects.
In the clinical setting, a primary metabolic disorder indicates that there is a 
deficiency in the lipid metabolism, and this is designated familial hypercholester-
olemia (FH). The FH follows an autosomal dominant pattern of inheritance and 
is characterised by an increase of high TC and LDL-C since birth. Earlier onset of 
atherosclerotic cardiovascular disease (ASCVD) is also seen [20, 21]. Studies show 
that FH arises from genetic mutations in the LDL receptor (LDLR) and from the 
action of proprotein convertase known as proprotein convertase 9 (PCSK9) when it 
mutates [22, 23]. Also, FH has been associated with mutations in the apolipoprotein 
B gene which impedes the binding of LDL particles to the LDL receptor gene [22, 23]. 
Exogenous causes Hepatic causes
• Alcohol
• Drug therapy including corticosteroids, isotretinoin, some 
oral contraceptives, select chemotherapeutic agents, and select 
antiretroviral agents




Endocrine/Metabolic causes Inflammatory disease
• Hypothyroidism/hypopituitarism • Systemic lupus erythematosus
• Diabetes mellitus types 1 and 2 • Juvenile rheumatoid arthritis
• Pregnancy Storage disease
• Polycystic ovary syndrome Glycogen storage disease
• Lipodystrophy • Gaucher disease
• Acute intermittent porphyria • Cystine storage disease
Renal causes • Juvenile Tay-Sachs disease
• Chronic renal disease • Niemann-Pick disease
• Haemolytic uremic syndrome Other causes
• Nephrotic syndrome • Kawasaki disease
Infectious causes • Anorexia nervosa
• Acute viral/bacterial infection • Childhood cancer survivor
• HIV infection • Idiopathic hypercalcemia
• Hepatitis • Klinefelter syndrome
Adapted from expert panel on integrated guidelines for cardiovascular health and risk reduction in children and 
adolescents, national heart, lung, and blood institute [3].
Table 2. 
Causes of secondary dyslipidaemia in children and adolescents.
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To date, reports of FH cases in Africa have been rare. There may be several explana-
tions for this. Perhaps, the gene implicated in the aetiology of FH is rare in African 
population. Even though cardiovascular diseases affect many Africans, it is still 
important for more studies to be performed on genetic factors that can cause dyslipi-
daemia. This would reduce the burden of cardiovascular disease in Africa.
Secondary causes of dyslipidaemia are due to “non-lipid” underlying condi-
tions rather than an inborn lipid metabolism disorder, some of which are shown in 
Table 2 [24].
5. Screening for dyslipidaemia in children
Usually, screening tests are performed on people who do not show any symp-
toms of disease to detect health problems or illnesses. The key goal of screening is 
early detection, to reduce the risk of illness, or to identify it early enough to treat 
it more effectively. Childhood lipid disorder screening is focused on the rationale 
for reducing the risk and severity of cardiovascular disease (CVD) in adulthood by 
early detection and management of paediatric dyslipidaemia. Universal screening 
for dyslipidaemia became the recommended practice in 2011 [25]. Currently, in 
most parts of Africa, screening for hyperlipidemia in children and adolescents is not 
routinely performed in clinical settings. However, it is appropriate to become aware 
of the latest guidelines for the diagnosis and treatment of dyslipidaemia by child 
health practitioners. The National Cholesterol Education Program Expert Panel on 
Blood Cholesterol in Children and Adolescents issued the first guidelines for pae-
diatric lipid screening in 1992 [26]. By 2011, when the American Heart Association 
[27] and the American Academy of Paediatrics included parameters to identify high 
and moderate risk individuals as seen in Table 3, thereafter, the guideline developed 
over several years with modifications [29].
The findings of National Heart Lung and Blood Institute (NHLBI) panel which 
performed a systematic review and grading of evidence related to the screening 
and treatment of CVD risk factors, including dyslipidaemia, were released in 2011 
in a combined effort to improve the assessment and management of cardiovascular 
disease risk factors [30, 31]. The universal screening for lipid disorders as recom-
mended in the guidelines means that all children between the ages of 9–11 should 
Risk factors Risk conditions
High-level risk factors
1. Hypertension requiring drug therapy 
(i.e., BP ≥99th percentile +5 mmHg)
2. Current cigarette smoker
3. BMI ≥97th percentile
4. Presence of high-risk conditions
5. Family history of premature CVD
Moderate-level risk factors
1. Hypertension not requiring 
drug therapy
2. BMI ≥95th percentile, but <97th 
percentile
3. HDL-C < 40 mg/dl
4. Presence of moderate-risk conditions
High-risk conditions
1. Type 1 and 2 diabetes mellitus
2. Chronic kidney disease/end-stage renal disease/
postrenal transplant
3. Post-orthotopic heart transplant
4. Kawasaki disease with current aneurysms
Moderate-risk conditions
1. Kawasaki disease with regressed coronary aneurysms
2. Chronic inflammatory diseases, such as:
• Systemic lupus erythematosus
• Juvenile rheumatoid arthritis
3. HIV
4. Nephrotic syndrome
Adapted from Kwiterovich, P. O., Jr. (2008). Recognition and management of dyslipidaemia in children and 
adolescents. J Clin Endocrinol Metab, 93(11), 4200–4209 [28].
Table 3. 
Risk factors and conditions for dyslipidaemia screening.
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get their lipids checked one time. This can be done by determining the plasma level 
of non-HDL-C with either a fasting lipid profile or a non-fasting test. This universal 
screening for dyslipidaemia was suggested because studies showed that 30–60 
percent of children and adolescents with extreme cholesterol elevations could be 
missed by using only a selective screening approach based on family history [31].
The universal screening technique is specifically intended to identify children 
with inherited dyslipidaemia as hypercholesterolemia runs in families. However, 
due to lifestyle and obesity factors, children with dyslipidaemia, high triglyceride 
levels and low HDL-C levels may also be identified. In most cases, dyslipidaemias 
are clinically silent and selective screening for children with family history does not 
identify a significant number of children with lipid disorders [31, 32].
6. Approach to diagnosis of dyslipidaemia in children
The risk factors for dyslipidaemia are basically those that have been estab-
lished to increase the likelihood of adults to develop ASCVD as listed in  
Table 3, while risk conditions are specific to paediatric guidelines and involve 
diseases that increase the risk of developing premature CVD [3]. There will be no 
noticeable clinical signs and symptoms for most children and adolescents with 
dyslipidaemia. The lack of clinical features is because, apart from individuals 
with Homozygous Familial Hypercholesterolemia (HoFH) that may have the first 
clinical clues in the first 10 years of life, most symptoms and signs only grow 
after decades [21]. Patients with HoFH are born with elevated LDL-C levels in 
their blood, and this is one of the reasons behind the early development of seri-
ous disease complications [21].
Physical signs, such as lipid deposits, bleeding, and atrophy, occur in the eyes, 
skin, and tendons. These signs may differ for each person and are therefore not 
necessarily invariable for the same disease. The heterozygous phenotype is generally 
present with tendon xanthomas, while the homozygous phenotype is present with 
both tendon and skin xanthomas. The characteristic lesion of familial hypercholes-
terolemia is the thickening of the tendons of Achilles. Symptoms caused by these 
deposits in the tendons and joints include chronic inflammation and joint pain, 
which can make it difficult for a person to live a good life. Cutaneous xanthelasmas 
of the eyelids can often be seen in patients with FH, but this symptom is not quite 
common. It should be noted that the diagnosis of xanthomas in the clinical exami-
nation is not only of diagnostic importance but may also signify the possibility of 
a cardiovascular event, as patients whose xanthomas have been observed in the 
clinical examination have been shown to suffer from more cardiovascular events. 
If there is a “white crescentic line” on the skin due to cholesterol accumulation, this 
also supports the diagnosis of hypercholesterolemia.
Of late, there are arguments surrounding universal screening of children and 
adolescents for dyslipidaemia, some favour universal screening, while others are 
against universal screening. While current data still classify approximately one 
third of children as having elevated lipid levels, some authors have documented 
the diagnosis of elevated lipid levels in many children without a family history 
of CVD or hypercholesterolemia [33]. Although it is more common in adults and 
youth with genetic disorders, selective screening may also be missed in many adults, 
particularly when their parents are young, free of CVD and unaware of their own 
lipid levels. Universal screening for these carriers can also be conducted to classify 
those with undiagnosed heterozygotes for familial hypercholesterolemia or those 
with more pronounced homozygotes who will then undergo more extensive care, 
including the possibility of drug therapy. In a meta-analysis, 88–96 percent of all 
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cases with a false-positive rate of less than 1% were detected in screening for family 
hypercholesterolemia in the primary treatment clinic [34].
Current literature tells us that risk factors for CVD are most observed in ado-
lescence, and these risk factors are still present in adulthood. Dietary and hygienic 
treatment and medication are effective for those who have this disease. It is there-
fore necessary for all children and adolescents to perform a separate lipoprotein 
test for each of them. However, it can be argued that screening for people who 
have never smoked should be universal, given the prevalence of obesity in young 
Africans, the epidemic of metabolic syndrome, and the fact that CVD is quickly 
becoming a cause of death for individuals under 55 years of age, and will likely be 
the leading cause of death for all adults under 65 [33].
However, as noted in another publication, concerns have been raised that several 
longitudinal studies [33] find that when the 75th percentile for triglyceride levels 
in children is used as a screening cut-off point, only half of those in need of adult 
treatment are identified by universal lipid screening. In one study, the sensitivity 
was much lower when screening occurred during puberty, which is likely to indicate 
a transient downward shift in LDL-C during this time of rapid growth and develop-
ment [35]. Another unresolved question is whether the detection of elevated TC or 
LDL-C in children and young adults suggests that these adults will develop prema-
ture CVD. If systematic screening for lipid and non-lipid risk factors for CVD was 
a standard of paediatric treatment, there would obviously be a need for national 
resources to recognise and treat those found to be at high risk of CVD.
7. Conclusion
Children and adolescents who are predisposed to dyslipidaemia are more likely 
to remain predisposed to dyslipidaemia throughout their lives. Interventions in 
childhood and adolescence are immensely helpful in helping to prevent the build-
up of fatty deposits in the arteries and other cardiovascular problems later in life. 
Therefore, abnormalities in the lipid profile of children and adolescents, particu-
larly those with other risk factors, must be identified early, followed, monitored, 
and treated, if possible. Health care providers should strive to examine, diagnose, 
and treat prevalent genetic conditions such as familial hypercholesterolemia that 
affect families for several generations. Lipid screening should be one of the routine 
therapies for children in Africa.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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